Thai network reported that according to Thai media news, the subunit vaccine (subunit vaccine) developed by Thai Baiya Phytopharm Company has previously entered the early human trial stage, baiya company has recruited 18-60-year-old volunteers to be vaccinated in September this year, all volunteers have no abnormalities after vaccination, and there have been no adverse reactions. Recently, the company once again issued a notice to recruit 61-75-year-old volunteers who have not yet received the new crown vaccine to receive the vaccine developed by the company and enter the first phase of human trials of the baiya sars cov-2 Vax 1 vaccine.
According to relevant personnel, the research team has also developed a 2nd generation vaccine to prepare to deal with the mutated virus, so that the Thai people can use Thailand's self-produced vaccine in mid-2022, it is expected that baiya's production can reach 60 million doses / year, and the company also plans to increase the production level to 300-500 million doses, when Thailand itself has mastered the research and development and production knowledge of vaccines, Thailand will be able to control the new crown epidemic or other types of viruses in a timely manner in the future.
(Source: To the point)